re: a serious event about to happen.
Not sure if the Stephen Spratt you mentioned is meant to be Dr Phillip Spratt (Transplant Unit Director).
If so, he was quoted 30 June 2003 in the SMH as follows ...
Phillip Spratt, director of heart surgery at Sydney's St Vincent's hospital, said trials of similar pumps overseas had been fraught with problems, including blood clots, organ damage, overheating and mechanical failure.
"There are great hopes held for these types of pumps which so far haven't come to fruition because they always seem to develop problems," he said.
"Those of us that are in the field of mechanical assistance do hope that this fulfills its promise because there's a huge number of patients out there who can benefit from a device like this."
If Dr Spratt is about to support the VCR trials, perhaps he can see a difference between ventrassist and the other LVADs in the market. That would be enough for me to think VCR is on the right track.
- Forums
- ASX - By Stock
- VCR
- going to $1.21
VCR
ventracor limited
going to $1.21, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VCR (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online